LNCaP human prostate cancer progression model

Urologic Oncology

Volumn 2, Issue 4, 1996, Pages 126-128

  Chung, Leland W K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012773693     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)82846-3     Document Type: Article

References (20)

1. Horoszewicz J, Leong S, Chu T, Wajsman Z, Friedman M, Papsidero L, Kim U, Chiu L, Katati S, Anya S and Sandberg A. The LNCaP cell line-A new model for studies on human prostatic carcinoma. Progress in Clin Biol Res 1980;37:115-32.
2. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
3. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HYE, Balian G, Chung LWK. Mouse models of human prostate cancer skeletal metastasis: Comparisons of mouse strain and route of tumor cell administration. Cancer Res. (submitted).
4. Cleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK. Acceleration of human prostate cancer growth in vivo by prostate and bone fibroblasts. Cancer Res 1991;51:3753-61.
5. Stephenson RA, Dinney CPN, Gohji K, Ordonez NG, Killion JJ, Fidler U. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951-6.
6. Pretlow TG, Delmoro CM, Dilley GG, Spadafora GG, Pretlow TP. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res 1991;51:3814-7.
7. Cleave ME, Hsieh JT, von Eschenbach AC, Chung LWK. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional stromalepithelial interaction in prostate carcinoma growth and metastasis. J Urol 1992;147:1151-9.
8. Chung LWK, Li W, Cleave ME, Hsieh HC, Wu HC, Sikes RA, Shau HYE, Bandyle M, Logothetis C, Rubin JS, von Eschenbach AC. Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem 1992;16H:99-105.
9. Pettway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion
10. JJ, Fidler U. Selection of highly metastatic variants of different human prostate carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-36.
11. Wu HS, Hsieh JT, Cleave ME, Brown NM, Pathak S, Chung LWK. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994;57:406-12.
12. Thalmann GN, Anezinis PE, Chang S-M, Shau HE, Kim E, Hopwood VL, Pathak S, von Eschenbach AC, Chung LWK. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
13. Hsieh JT, Wu HC, Cleave ME, von Eschenbach AC, Chung LWK. Autoregulation of prostate-specific antigen gene expression in human prostate carcinoma (LNCaP) subline. Cancer Res 1993;53:2852-7.
14. Thalmann GN, Sikes RA, Chang S-M, Johnston DA, van Eschenbach AC, Chung LWK. Suramin-induced decrease in prostatespecific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996;88:794-801.
15. Eisenberge MA, Nelson WG. How much can we rely on the level of prostatic specific antigen as an end-point for evaluation of clinical trials? A word of caution (Editorials). J Natl Cancer Inst 1996;88:779-81.
16. Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LWK. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Human Gene Therapy 1996;7:1683-91.
17. Chen M, Shen JC, Thalmann GN, Sikes RA, von Eschenbach AC, Chung LWK. Androgen-independent human prostate cancer progression: The isolation of novel stage-specific sequences using differential mRNA display. J Urol 1995;153:267A.
18. Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LWK, Visakorpi T. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity, and metastatic potential in a prostate cancer model. Brit J Cancer (In Press).
19. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. Characterization of a novel androgensensitive, prostate-specific, antigen-producing, prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-48.
20. Nagabhushan M, Miller DM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.